

#5-8-354, Office No. 1106, Ratna Block Raghav Ratna Towers, Chirag Ali Lane, Abids Hyderabad, Telangana - 500001 | Tel: 040 23314435 Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No. L67120TG1994PLC018956

Date: 09.08.2023

To, BSE Limited, P.J. Towers, Dalal Street, Mumbai - 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting held on 09.08.2023

Ref: Company's Letter dated 03.08.2023

Unit: Trimurthi Limited

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Trimurthi Limited** at its meeting held on Wednesday, the 09th day of August 2023 at 11:00 a.m. at the registered office of the Company situated at 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad - 500001, Telangana, approved the following:

- 1. Unaudited financial results for the quarter ended 30.06.2023. (Enclosed)
- Limited Review Report as per Regulation 33 of SEBI (LO&DR) Regulations, 2015 for the Quarter ended 30.06.2023(Enclosed)
- 3. Resignation of Mr. Arun Bhangadia from the post of Chairman & Managing Director w.e.f., 09.08.2023
- Appointment of Mr. Aditya Bhangadia as the Chairman and an Additional Director (Whole time director) of the Company w.e.f., 09.08.2023
- 5. Appointment of Mr. Ravi Bhangadia as an Additional Director (Managing director) of the Company w.e.f., 09.08.2023



#5-8-354, Office No. 1106, Ratna Block Raghav Ratna Towers, Chirag Ali Lane, Abids Hyderabad, Telangana - 500001 | Tel: 040 23314435 Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No. L67120TG1994PLC018956

The details required under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 are enclosed.

This is for the information and records of the Exchange, please.

The meeting concluded at 4:30 p.m.

Thanking you.

For Trimurthi Limited

Ravi Bhangadia

Chairman and Whole time Director

DIN: 03434400 Encl. as above



#5-8-354, Office No. 1106, Ratna Block Raghav Ratna Towers, Chirag Ali Lane, Abids Hyderabad, Telangana - 500001 | Tel: 040 23314435 Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No. L67120TG1994PLC018956

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 related to appointments and resignations as mentioned below:

| S. No | Particulars | Mr. Arun Kumar Bhangadia | | | |
|-------|--|--|--|--|--|
| 1 | Reason for Appointment/Resignation | Resignation | | | |
| 2. | Date of Appointment/Cessation and terms of appointment | 09.08.2023 | | | |
| 3. | Brief Profile (in case of appointment) | NA | | | |
| 4. | Disclosure of relationships between directors | Brother of Mr. Arvind Kumar Bhangadia, director of the Company | | | |
| 5. | Shareholding, if any in the company | 15,42,200 Equity Shares | | | |





#5-8-354, Office No. 1106, Ratna Block Raghav Ratna Towers, Chirag Ali Lane, Abids Hyderabad, Telangana - 500001 | Tel: 040 23314435 Email: info@trimurthidrugs.com, Website: www.trimurthidrugs.com CIN No. L67120TG1994PLC018956

| S. No Particulars 1. Reason for Appointment/Resignation | | Mr. Aditya Bhangadia | Mr. Ravi Bhangadia Appointment | | | |
|--|--|--|--|--|--|--|
| | | Appointment | | | | |
| 2. | Date of Appointment/Ces sation and terms of appointment | 09.08.2023 Appointed upto the conclusion of coming Annual General Meeting | 09.08.2023 Appointed upto the conclusion of coming Annual General Meeting | | | |
| 3. | Brief Profile (in case of appointment) | Aditya Bhangadia holds an MBA degree in Marketing & Finance from a prestigious university in Singapore. He has experience in marketing and positioning | of Technology in Civil Engineering and a Diploma in Family Business | | | |
| 4. | Disclosure of relationships between directors | Son of Mr. Arun Kumar Bhangadia, Brother of Ravi Bhandgadia and Nephew of Arvind Bhangadia | Son of Mr. Arun Kumar Bhangadia, Brother of Aditya Bhandgadia and Nephew of Arvind Bhangadia | | | |
| 5. | Shareholding, if any in the company | 1,65,000 Equity Shares | 66,333 Equity Shares | | | |



To, Date: 09.08.2023

The Board of Directors, Trimurthi Limited 5-8-354/1106, Office no. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Abids, Hyderabad-500001 Telangana

Dear Sir/Madam,

Sub: Resignation as Director of the Company

Due to my commitments and personal pre-occupations, I am not in a position to continue as a Chairman and Managing Director of Trimurthi Limited. Hence, I tender my resignation as Chairman and Managing Director of the Company w.e.f., 09.08.2023

I take this opportunity to thank my colleagues on the Board for their continued support and wish them a great success in all their future endeavors.

Further, I would also like to confirm that there is no other material reason other than the one mentioned above, for my resignation from the Board of the Company.

Thanking you.

Yours truly,

Arun Kumar Bhangadia

(DIN: 00021024)



#5-8-354, Office No. 1106, Ratna Block Raghav Ratna Towers, Chirag Ali Lane, Abids Hyderabad, Telangana - 500001 | Tel: 040 23314435

Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No. L67120TG1994PLC018956

TRIMURTHI LIMITED

| | PARTICULARS | QUARTER ENDED | | | YEAR ENDED |
|----|---|---------------------------|-------------------------|---------------------------|-------------------------|
| | | 30.06.2023 (UNAUDITED) | 31.03.2023 (AUDITED) | 30.06.2022 (UNAUDITED) | 31.03.2023 (AUDITED) |
| A. | PARTICULARS OF SHARE HOLDING | | | | |
| 1. | Public Share Holding | | | | |
| | - Number of Shares | 2679267 | 2679267 | 2679267 | 2679267 |
| | - Percentage of shareholding | 33.08% | 33.08% | 33.08% | 33.08% |
| 2. | Promoters and promoter group shareholding | | | | |
| | a. Pledged / encumbured | | | | 27.1 |
| | - No of Equity Shares | -Nil- | -Nil- | -Nil- | -Nil- |
| | - Percentage of Shares (of the shareholding of promoter and promoter group) | -Nil- | -Nil- | -Nil- | -Nil- |
| | - Percentage of Shares (of the total share capital of the company) | -Nil- | -Nil- | -Nil- | -Nil- |
| | b. Non encumbured | | | | |
| | - No of Equity Shares | 5420733 | 5420733 | 5420733 | 5420733 |
| | - Percentage of Shares (of the shareholding of promoter and promoter group) | 100.00% | 100.00% | 100.00% | 100.00% |
| | - Percentage of Shares (of the total share capital of the company) | 66.92% | 66.92% | 66.92% | 66.92% |

| | Particulars | 3 Months Ended (30/06/2023) |
|----|---|------------------------------|
| В. | Investor Complaints | |
| | Pending at the beginning of the quarter | -NIL- |
| | Received during the quarter | -NIL- |
| _ | Disposed during the quarter | -NIL- |
| _ | Remaining unsolved during the quarter | -NIL- |

TRIMURTHI LIMITED

Segment Reporting

| PARTICULARS | QU | QUARTER ENDED | | |
|---|---------------------------|-------------------------|---------------------------|-------------------------|
| | 30.06.2023 (UNAUDITED) | 31.03.2023 (AUDITED) | 30.06.2022 (UNAUDITED) | 31.03.2023 (AUDITED) |
| I. Segment Revenue | | | | |
| a. Pharma Business | 4.73 | 14.59 | 1.10 | 21.32 |
| b. Financial Services | 0.00 | 10.04 | 5.63 | 27.27 |
| c. Investments | 190.64 | 13.21 | | 24.30 |
| d. Trading in Shares | 0.00 | 71.99 | 5.38 | 119.14 |
| e. Foods | 4.59 | | | |
| Total | 199.96 | 109.83 | 12.10 | 192.03 |
| Less: Inter Segment Revenue | | | | |
| Net Sales/ Income From Operations | 199.96 | 109.83 | 12.10 | 192.03 |
| 2. Segment Profits (Before tax & Interest From Each Segment) | | | | |
| a. Pharma Business | 0.94 | 5.29 | 0.17 | 4.83 |
| b. Financial Services | 4.59 | 10.04 | 5.63 | 27.27 |
| c. Investments | | 13.21 | | 24.30 |
| d. Trading in Shares | (21.06) | (27.13) | (11.62) | (62.25 |
| e. Foods | | | | |
| Total | (15.53) | 1.42 | (5.83) | (5.85 |
| Less: | | | | |
| i. Interest | | | | |
| ii. Other Un-allocable expenses net off | | | | |
| iji, Un-allocable Income | | | | |
| Total Profit Before Tax | (15.53) | 1.42 | (5.83) | (5.85 |
| 3. Capital Employed | | | | |
| a. Pharma Business | 55.61 | 55,82 | 70.97 | 55.82 |
| b. Financial Services | 0.00 | 7.78 | 102.13 | 7.78 |
| c. Investments | 308.80 | 277.52 | 203.20 | 277.52 |
| d. Trading in Shares | 343.50 | 378.39 | 341,98 | 378.3 |
| e. Foods | | | - | |
| Total | 707.92 | 719.51 | 718.27 | 719.51 |

Notes:

- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- 2 The financial results were reviewed by the Audit Committee and then approved at the meeting of the Board of Directors of the Company held on 09-08-2023
- 3 The above financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34- Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued there under and the other accounting principles generally accepted in India.
- 4 The results are also available on the webiste of the Company

Place : Hyderabad Date : 09-8-2023




#5-8-354, Office No. 1106, Ratna Block Raghav Ratna Towers, Chirag Ali Lane, Abids Hyderabad, Telangana - 500001 | Tel: 040 23314435 Email: info@trimurthidrugs.com Website: www.trimurthidrugs.com CIN No. L67120TG1994PLC018956

TRIMURTHI LIMITED

Regd Off: 5-8-354/1106, Office No. 1106, Ratna Block, Raghav Ratna Towers, Chirag Ali Lane, Hyderabad, Telangana – 500001 STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER I ENDED 30th JUNE 2023

(Amount in lakhs except EPS)

| | QUARTER ENDED YEA | | | YEAR ENDED |
|--|---------------------------|-------------------------|---------------------------|-------------------------|
| PARTICULARS | 30.06.2023 (UNAUDITED) | 31.03.2023 (AUDITED) | 30.06.2022 (UNAUDITED) | 31.03.2023 (AUDITED) |
| . INCOME NCOME FROM OPERATIONS OTHER INCOME | 195.37 4.59 | 86.58 23.25 | 6.47 5.63 | 140.46 51.57 |
| FOTAL INCOME | 199.96 | 109.83 | 12.10 | 192.03 |
| 2. EXPENSES | | | | * |
| PURCHASES COST OF MATERIALS CONSUMED | 175.72 | 92.67 | 3.75 | 164.09 |
| MANUFACTURING EXPENSES INCREASE/(DECREASE) IN STOCK IN TRADE | 10.40 | (4.67) | (0.20) | (28.86) 1.50 |
| RENT EMPLOYEE BENEFITS EXPENSE FINANCE COSTS | 5.04 | 10.47 | 6.76 | 31.18 |
| DEPRECIATION AND AMORTISATION EXPENSES | 1.07 23.25 | 1.41 8.23 | 0.71 6.92 | 5.62 24.36 |
| OTHER EXPENSES | 215.48 | 108.41 | 17.93 | 197.88 |
| TOTAL EXPENSES | | | | |
| 3. PROFIT/(LOSS) FROM BEFORE EXCEPTIONAL ITEMS AND TAX (1-2) | (15.52) | 1.42 | (5.83) | (5.85) |
| 4. EXCEPTIONAL ITEMS/ PRIOR PERIOD ITEMS | | | | |
| 5. PROFIT/(LOSS) FROM CONTINUING OPERATIONS BEFORE TAX (3-4) | (15.52) | 1.42 | (5.83) | (5.85) |
| 6. TAX EXPENSES | 1.35 | (0.04) | (0.21) | (0.15) |
| -CURRENT TAX | | | | |
| -TAX ADJUSTMENTS RELATING TO EARLIER YEARS | | | | |
| -DEFERRED TAX (NET) | 1.35 | (0.04 | (0.21) | (0.15) |
| | (16.87 | 1.38 | (6.04) | (5.99) |
| 7. NET PROFIT/(LOSS) FROM CONTINUING OPERATIONS AFTER TAX (5-6) | (10.07 | 1.50 | (0.00) | |
| 8.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS | | | | |
| 9.TAX EXPENSES FOR DISCONTINUED OPERATIONS | 2 | | | |
| 10.PROFIT /(LOSS) FROM DISCONTINUED OPERATIONS (AFTER TAX) (8 9) | | | | |
| 11.PROFIT/(LOSS) FOR THE PERIOD (7+10) | (16.87 | 1.38 | (6.04) | (5.99 |
| 12.OTHER COMPREHENSIVE INCOME | | | | |
| A. (i) ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS | 5.28 | 1.20 | - | 1.20 |
| (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL NOT BE RECLASSIFIED TO PROFIT OR LOSS | | | | |
| B. (i) ITEMS THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS | | | | |
| (ii) INCOME TAX RELATING TO ITEM THAT THAT WILL BE RECLASSIFIED TO PROFIT OR LOSS | | | | |
| 13.TOTAL COMPREHENSIVE INCOME FOR THE PERIOD (11+12) (COMPRISING PROFIT (LOSS) AND OTHER COMPREHENSIVE INCOME) | (11.5 | 9) 2.5 | 8 (6.04 | (4.75 |
| 14.EARNINGS PER EQUITY SHARE (FOR CONTINUING OPERATION): (i) BASIC (ii) DILUTED | (0.2 (0.2 | 2000 | and Samuel | |
| 15.EARNINGS PER EQUITY SHARE (FOR DISCONTINUING OPERATION): (i) BASIC (ii) DILUTED 16.EARNINGS PER EQUITY SHARE (FOR CONTINUING AND | | | | |
| DISCONTINUING OPERATION): | 0345 | M) | 10.00 | 7) (0.0 |
| (i) BASIC | (0.2 | and the second | | ** |
| (ii) DILUTED | (0 | | DAH | |



Tel. : (91-40) 2332 6666, 2331 2554 2339 3967, 2332 1470

FAX : (91-40) 2339 2474 E-mail : pmurali.co@gmail.com

info@pmurali.com Website: www.pmurali.com

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended


Review report to The Board of Directors Trimurthi Limited

We have reviewed the accompanying statement of unaudited financial results of TRIMURTHI LIMITED (the "Company") for the quarter ended June 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting, ('Ind AS 34,') prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





Tel.

: (91-40) 2332 6666, 2331 2554

2339 3967, 2332 1470

FAX : (91-40) 2339 2474 E-mail

: pmurali.co@gmail.com

info@pmurali.com Website: www.pmurali.com

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS 34 prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.

Chartered Accountants

FRN: 007257S

A.Krishna Rao

Partner

M.No. 020085

UDIN: 23020085BGQXRX3034

Hyderabad

Fered Acco

Place: Hyderabad Date: 09-08-2023